News and Analysis
Nature Reviews Drug Discovery 3, 295-296 (April 2004) | doi:10.1038/nrd1362
Fresh from the Pipeline: Tadalafil and vardenafil
Katherine Neumeyer2 & Peter Kirkpatrick1
Top of page
Abstract
In 2003, two inhibitors of phosphodiesterase 5 (PDE5) — tadalafil (Cialis; Lilly ICOS) and vardenafil hydrochloride (Levitra; Bayer/ GlaxoSmithKline) — were approved by the US FDA for the treatment of erectile dysfunction. Can they challenge the dominance of the first PDE5 inhibitor, sildenafil citrate (Viagra; Pfizer), which rapidly became a blockbuster following its market entry in the late 1990s?
Author affiliations
- Peter Kirkpatrick is at Nature Reviews Drug Discovery.
- Katherine Neumeyer is at Decision Resources Inc., 260 Charles Street, Waltham, Massachusetts 02453, USA.
Correspondence to: Katherine Neumeyer2 Email: kneumeyer@dresources.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
